Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 2371 to 2380 of 2733 total matches.
Rethinking Warfarin for Atrial Fibrillation
The Medical Letter on Drugs and Therapeutics • Sep 30, 2013 (Issue 1426)
competing with warfarin (Coumadin,
and others) for the oral anticoagulant market.1
NEW ORAL ANTICOAGULANTS ...
Full-page newspaper advertisements and a series of television
commercials have urged patients with atrial fibrillation
to "rethink warfarin" in favor of Eliquis (apixaban –
Bristol-Myers Squibb). Apixaban is the latest of 3 new oral
anticoagulants now competing with warfarin (Coumadin,
and others) for the oral anticoagulant market.
In Brief: Suspension of Johnson & Johnson COVID-19 Vaccine Lifted (online only)
The Medical Letter on Drugs and Therapeutics • May 17, 2021 (Issue 1624)
million doses of the single-dose vaccine had been
administered in the US at the time of the review.1-4 ...
On April 23, 2021, on advice from the Advisory
Committee on Immunization Practices (ACIP), the
FDA and CDC recommended that use of the Johnson
& Johnson adenovirus-based COVID-19 vaccine
resume despite its association with development of
thrombosis with thrombocytopenia syndrome (TTS).
Administration of the vaccine had been paused on April
13 because of 6 reports of TTS, but after completing a
data review that identified a further 9 cases associated
with the formulation, the agencies concluded that the
benefits of the vaccine outweighed its risks. About
7.98 million doses of the...
In Brief: Low-Dose Chlorthalidone (HemiClor) for Hypertension
The Medical Letter on Drugs and Therapeutics • Jul 21, 2025 (Issue 1733)
(Edarbyclor) and atenolol (Tenoretic, and
generics).1,2
CHLORTHALIDONE — Chlorthalidone is more potent
than ...
The FDA has approved a 12.5-mg tablet formulation
of the thiazide-like diuretic chlorthalidone (HemiClor –
Ingenus) for treatment of hypertension. Chlorthalidone
has been available for years in 15-, 25-, and 50-mg
tablets (Thalitone, and generics) and in fixed-dose
combinations with azilsartan medoxomil (Edarbyclor)
and atenolol (Tenoretic, and generics).
Med Lett Drugs Ther. 2025 Jul 21;67(1733):118 doi:10.58347/tml.2025.1733e | Show Introduction Hide Introduction
In Brief: Aflibercept (Eylea HD) for Macular Edema Following Retinal Vein Occlusion
The Medical Letter on Drugs and Therapeutics • Mar 30, 2026 (Issue 1751)
-related macular degeneration,
diabetic macular edema, and diabetic retinopathy.1
A CLINICAL STUDY ...
Eylea HD (Regeneron), which contains 8 mg of the
vascular endothelial growth factor (VEGF) inhibitor
aflibercept, has now been approved by the FDA for
intravitreal treatment of macular edema following
retinal vein occlusion (RVO). A 2-mg dose of aflibercept
(Eylea) was approved previously for this indication.
Eylea and Eylea HD are also approved for treatment of
neovascular (wet) age-related macular degeneration,
diabetic macular edema, and diabetic retinopathy.
Med Lett Drugs Ther. 2026 Mar 30;68(1751):56 doi:10.58347/tml.2026.1751b | Show Introduction Hide Introduction
Comparison Table: Some Oral/Transdermal Opioid Analgesics (online only)
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022 (Issue 1665)
have been reported,
particularly after >1 month of use
Hyperalgesia, worsening pain that cannot be overcome ...
View the Comparison Table: Some Oral/Transdermal Opioid Analgesics
The Viralizer For The Common Cold
The Medical Letter on Drugs and Therapeutics • Jan 27, 1989 (Issue 784)
or omission. Copyright 1988-2002. The Medical Letter, Inc.
Phone: 1-800-211-2769 Fax: 1-914-632-1733 WEB ...
Recently, full-page advertisements have appeared in the New York Times and other newspapers promoting the Viralizer (Viral Response Systems, Greenwich, CT), a heated nebulizer-sprayer device marketed for treatment of colds, sore throats, allergy and sinusitis symptoms. The device is available without a prescription for about $30 to $40.
Desflurane - A New Volatile Anesthetic
The Medical Letter on Drugs and Therapeutics • Apr 30, 1993 (Issue 895)
. Copyright 1988-2002. The Medical Letter, Inc.
Phone: 1-800-211-2769 Fax: 1-914-632-1733 WEB SITE: http ...
Desflurane (Suprane - Anaquest), an inhalation anesthetic, has been approved by the US Food and Drug Administration for induction and maintenance of general anesthesia in adults and for maintenance of anesthesia in infants and children. Like isoflurane (Forane), the last volatile anesthetic to become available in the USA (Medical Letter, 23:112, 1981), the new agent is a halogenated methyl ethyl ether, differing from isoflurane in the substitution of a fluorine for a chlorine atom.
Pallidotomy for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Dec 06, 1996 (Issue 989)
. The Medical Letter, Inc.
Phone: 1-800-211-2769 Fax: 1-914-632-1733 WEB SITE: http://www.medletter.com ...
Ablation of the globus pallidus, an old treatment for Parkinsons disease, is being tried again, using more refined stereotactic techniques, improved brain imaging and new methods for recording neuronal activity (CW Olanow, Ann Neurol, 40:341, September 1996).
Safety of Dronedarone (Multaq)
The Medical Letter on Drugs and Therapeutics • Dec 12, 2011 (Issue 1379)
for oral treatment
of paroxysmal or persistent (non-permanent) atrial
fibrillation or atrial flutter.1 ...
Dronedarone (Multaq – Sanofi), an analog of amiodarone,
was approved by the FDA in 2009 for oral treatment
of paroxysmal or persistent (non-permanent) atrial
fibrillation or atrial flutter. Amiodarone (Cordarone, and
others) is more effective for this indication, but its use is
often limited by its adverse effects, including thyroid and
pulmonary toxicity.
Prosthetic Heart Valves
The Medical Letter on Drugs and Therapeutics • Aug 20, 2012 (Issue 1397)
than those in the aortic position.1
Mechanical valves are preferred for younger patients
( ...
Prosthetic heart valves have been used effectively in
patients with mitral and aortic valvular heart disease
for more than 50 years, but no replacement valve
developed to date is suitable for all types of patients.
